Compare
Blend Labs, Inc. vs Cardlytics, Inc. vs System1, Inc. vs Health Catalyst, Inc.
| Latest fiscal year | Blend Labs, Inc. BLND | Cardlytics, Inc. CDLX | System1, Inc. SST | Health Catalyst, Inc. HCAT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $123.58M | $233.27M | $266.13M | $311.14M |
| Revenue growth (YoY) | +6.8% | -16.2% | -22.6% | +1.5% |
| Gross margin | 73.8% | n/a | 37.7% (computed) | n/a |
| Operating margin | -17.6% | -43.6% | -23.3% | -51.7% |
| Net margin | -5.5% | -44.4% | -24.6% | -57.2% |
| Net income | -$6.80M | -$103.49M | -$65.34M | -$177.97M |
| EPS (Diluted) | -$0.10 | -$1.95 | -$8.32 | -$2.55 |
| Operating cash flow | $11.51M | $9.29M | -$4.15M | $731.0K |
| Free cash flow | -$81.0K | $8.81M | -$4.19M | -$237.0K |
| Cash & equivalents | $43.58M | $48.72M | $86.89M | $50.81M |
| Total assets | $170.04M | $285.64M | $404.97M | $502.64M |
| Total liabilities | $41.02M | $292.15M | $387.55M | $256.86M |
| Shareholders' equity | -$30.47M | -$6.51M | $30.47M | $245.78M |
| Return on year-end equity | n/a | n/a | -214.5% | -72.4% |
| Shares outstanding | 256.04M | 54.51M | n/a | 72.03M |
Revenue, most recent five fiscal years
| Fiscal year | Blend Labs, Inc. | Cardlytics, Inc. | System1, Inc. | Health Catalyst, Inc. |
|---|---|---|---|---|
| Latest | $123.58M Ended 2025-12-31 | $233.27M Ended 2025-12-31 | $266.13M Ended 2025-12-31 | $311.14M Ended 2025-12-31 |
| 1 year earlier | $115.76M Ended 2024-12-31 | $278.30M Ended 2024-12-31 | $343.93M Ended 2024-12-31 | $306.58M Ended 2024-12-31 |
| 2 years earlier | $109.55M Ended 2023-12-31 | $309.20M Ended 2023-12-31 | $401.97M Ended 2023-12-31 | $295.94M Ended 2023-12-31 |
| 3 years earlier | $235.20M Ended 2022-12-31 | $298.54M Ended 2022-12-31 | n/a | $276.24M Ended 2022-12-31 |
| 4 years earlier | $234.50M Ended 2021-12-31 | $267.12M Ended 2021-12-31 | $688.39M Ended 2021-12-31 | $241.93M Ended 2021-12-31 |